Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Nintendo Slips To Loss In FY11 - Quick Facts

4/26/2012 3:24 AM ET

Nintendo (NTDOY.PK) posted fiscal year 2011 consolidated net loss of 43.2 billion yen or 337.86 yen per share versus profit of 77.62 billion yen or 606.99 yen per share a year ago.

Net sales declined to 647.65 billion yen from 1.01 trillion yen last year.

Looking ahead to the fiscal year ending March 31, 2013, the company projects net income of 20 billion yen, on net sales of 820 billion yen.

Click here to receive FREE breaking news email alerts for Nintendo Co. Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates. While buying interest was relatively subdued, stocks moved modestly higher over the course of the trading day on Tuesday. The strength on the day offset the weakness seen in the previous session, with the Dow and the S&P 500 reaching new record closing highs. The major averages gave back some ground in late-day trading but remained in positive territory. While a recent series of scandals have caused headaches for the White House, the results of a Washington Post-ABC News poll released Tuesday suggest that the news has not had an impact on President Barack Obama's approval rating. The poll showed that 51 percent of Americans approve of the way Obama is handling his job as president compared to 44 percent that disapprove.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.